Meetings

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at Harvard University's David Rubenstein Treehouse in Boston. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

ARDD 2026 has announced that Fiona Marshall, President of Biomedical Research at Novartis, will deliver a featured presentation, "Reimagining Drug Discovery Through the Lens of Aging Biology," at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

The 11th HKU Quarterly Forum on Chinese Economy, hosted by HKU Business School’s Institute of China Economy (ICE), in partnership with the Shanghai Jiao Tong University Hong Kong Alumni Association, was held on 31 July, at HKU iCube in Central, Hong Kong.

On 19 July 2026, the Urban Systems Institute (USI) of the University of Hong Kong (HKU), in collaboration with the Institute for Climate and Carbon Neutrality (ICCN) at HKU, the State Key Laboratory of Subtropical Building and Urban Science Hong Kong Base (SKL-SBUS-HK), the Otto Poon Charitable Foundation Smart Cities Research Institute, The Hong Kong Polytechnic University, and the IEEE Geoscience and Remote Sensing Society Hong Kong Chapter (GRSS-HK), successfully hosted the inaugural Urban Systems Forum under the theme "Advanced Modeling of Urban Systems for Sustainable Cities." The Forum served as a high-level international academic platform, fulfilling USI's core mission to advance the sciences of urban systems and deepen their practical applications.

The Smart QS Hackathon 2026, co-organised for the first time by the Housing Bureau and the Hong Kong Housing Authority (HA), Cyberport, and the University of Hong Kong (HKU), was officially launched today (July 29) with a welcome ceremony and briefing session held at Cyberport. The Hackathon aims to explore innovative applications of Artificial Intelligence (AI) in Quantity Surveying (QS) through cross-sector collaboration, facilitating the intelligent transformation of the construction industry and enhancing the management and service effectiveness of public works.

The 8th annual Japan SciCom Forum (JSF) will take place at Nagoya University on October 20–21, 2026.

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will attend the conference and deliver two high-profile sessions—a panel discussion alongside top industry experts on "AI's Race to Reinvent Medicine", and a solo keynote address exploring "How to Address Diseases and Aging Simultaneously Using Frontier AI".

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway

Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors

Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, will participate in Cure’s virtual fireside chat, “Racing to Cures: US–China Biomedical Competitiveness,” on July 27 from 10:00 to 11:00 PM Beijing Time. The discussion will explore the competitive landscape and areas of collaboration between the United States and China in biomedical innovation.